Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality. CA Cancer J Clin. 71(3):209–49

Article  PubMed  Google Scholar 

Xia C, Dong X, Li H, Cao M, Sun D, He S et al (2022) Cancer statistics in China and United States, 2022: profiles, trends, and. Chin Med J 135(5):584–90

Article  PubMed  PubMed Central  Google Scholar 

Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS et al (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for. Lancet 385(9972):977–1010

Article  PubMed  Google Scholar 

Su GL, Altayar O, O’Shea R, Shah R, Estfan B, Wenzell C et al (2022) AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Gastroenterology 162(3):920–34

Article  PubMed  Google Scholar 

Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W et al (2023) Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 20(4):203–22

Article  PubMed  Google Scholar 

Lin YY, Tan CT, Chen CW, Ou DL, Cheng AL, Hsu C (2018) Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular. Semin Liver Dis 38(4):379–88

Article  CAS  PubMed  Google Scholar 

Xu J, Shen J, Gu S, Zhang Y, Wu L et al (2021) Camrelizumab in Combination with Apatinib in Patients with Advanced. Clin Cancer Res 27(4):1003–11

Article  CAS  PubMed  Google Scholar 

Vogel A, Saborowski A (2022) Medical therapy of HCC. J Hepatol 76(1):208–10

Article  PubMed  Google Scholar 

Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al (2022) Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab. J Hepatol 76(4):862–73

Article  CAS  PubMed  Google Scholar 

Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V et al (2022) Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 19(3):151–72

Article  CAS  PubMed  Google Scholar 

Chen M, Jiang M, Wang X, Shen L, Li J (2022) Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous. Expert Opin Biol Ther. 22(10):1227–32

Article  CAS  PubMed  Google Scholar 

Liu RR, Gu SZ, Zhou T, Lin LZ, Chen WC, Zhong DS et al (2023) [A phase I study of subcutaneous envafolimab (KN035) monotherapy in Chinese. Zhonghua Zhong Liu Za Zhi 45(10):898–903

CAS  PubMed  Google Scholar 

Papadopoulos KP, Harb W, Peer CJ, Hua Q, Xu S, Lu H et al (2021) First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain. Oncologist 26(9):e1514–e25

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Deng Y, Zhang W, Zhou AP, Guo W, Yang J et al (2021) Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch. J Hematol Oncol 14(1):021–01095

Article  CAS  Google Scholar 

Guo J, Zhao J, Xu Q, Huang D (2022) Resistance of Lenvatinib in Hepatocellular Carcinoma. Curr Cancer Drug Targets 22(11):865–78

Article  CAS  PubMed  Google Scholar 

Al-Salama ZT, Syed YY, Scott LJ (2019) Lenvatinib: A Review in Hepatocellular Carcinoma. Drugs 79(6):665–74

Article  CAS  PubMed  Google Scholar 

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–90

Article  CAS  PubMed  Google Scholar 

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163–1173

Article  CAS  PubMed  Google Scholar 

Zhao Y, Zhang YN, Wang KT, Chen L (2020) Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to. Biochim Biophys Acta Rev Cancer. 1:188391

Article  Google Scholar 

Wiegering A, Korb D, Thalheimer A, Kämmerer U, Allmanritter J, Matthes N et al (2014) E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates. Neoplasia 16(11):972–81

Article  PubMed  PubMed Central  Google Scholar 

Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F et al (2018) Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro. Oncol Rep 39(5):2225–34

CAS  PubMed  Google Scholar 

Kimura T, Kato YU, Ozawa Y, Kodama K, Ito J, Ichikawa K et al (2018) Immunomodulatory activity of lenvatinib contributes to antitumor activity in the. Cancer Sci 109(12):3993–4002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M et al (2020) Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable. J Clin Oncol 38(26):2960–70

Article  PubMed  PubMed Central  Google Scholar 

Markham A (2022) Envafolimab: First Approval. Drugs 82(2):235–40

Article  CAS  PubMed  Google Scholar 

Fan S, Gai C, Li B, Wang G (2023) Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI-H solid. Oncol Lett. 26(2):1

Article  Google Scholar 

Galle PR, Dufour JF, Peck-Radosavljevic M, Trojan J, Vogel A (2021) Systemic therapy of advanced hepatocellular carcinoma. Future Oncol 17(10):1237–51

Article  CAS  PubMed  Google Scholar 

Wang Y, Deng B (2023) Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev 42(3):629–52

Article  PubMed  Google Scholar 

Vogel A, Bathon M, Saborowski A (2021) Advances in systemic therapy for the first-line treatment of unresectable HCC. Expert Rev Anticancer Ther 21(6):621–8

Article  CAS  PubMed  Google Scholar 

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable. Lancet 391(10126):1163–73

Article  CAS  PubMed  Google Scholar 

Qin S, Bi F, Gu S, Bai Y et al (2021) Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic. J Clin Oncol 39(27):3002–11

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY et al (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379(1):54–63

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously. Lancet Oncol 19(7):940–52

Article  PubMed  Google Scholar 

Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329–38

Article  CAS